|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
The Auto Beat
Byte of the Apple
Europe Insight
Eye on Asia
Getting In
Investing Insights
The New Entrepreneur
NEXT: Innovation Tools & Trends
On Media
Technology at Work
The Tech Beat
Traveler's Check
TECHNOLOGY
Product Reviews
Tech Stats
Hands On
AUTOS
Home Page
Auto Reviews
Car Care & Safety
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip FINANCE Investing: Europe Annual Reports Bloomberg BW50 SCOREBOARDS Hot Growth Companies: 2008 Mutual Funds Info Tech 100 B-SCHOOLS Undergrad Programs Rankings & Profiles |  |
AUGUST 22, 2005
New River May Have A "Blockbuster" For ADHD  New River Pharmaceuticals (NRPH
) has yet to make a dime -- but investors love it. It rocketed to a high of 38.75 on Aug. 10, up from 14 on Dec. 30. It is developing novel products designed as safer, improved versions of widely prescribed drugs. Its most advanced compound is NRP104, which some say may become the lead remedy for attention-deficit hyperactivity disorder (ADHD). New River will file later this year with the Food & Drug Administration a new-drug application for NRP104, which is in the final stage of its Phase 3 clinical trials. Andrew Forman of investment firm WR Hambrecht expects profits of 61 cents on sales of $119 million in 2007 and $2.48 on sales of $399 million in 2008. His stock price target is 52. New River has teamed up with Shire Pharmaceuticals Group (SHPGY
), which sells the current leading drug for ADHD -- called Adderall XR, whose patent expires in late 2006. Adderall sales in the second quarter were up 43%, to $205 million. Shire is expected to focus on NRP104 when Adderall's patent expires. Wen-Tse Tseng, managing director at William D. Witter, which owns shares, says NRP104 is a "blockbuster with potential peak annual sales of $1 billion."
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial Get BusinessWeek directly on your desktop with our RSS feeds.  Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2005, Bloomberg L.P.Terms of Use | Privacy Notice |
Printer-Friendly Version